DE60121913D1 - ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS - Google Patents

ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS

Info

Publication number
DE60121913D1
DE60121913D1 DE60121913T DE60121913T DE60121913D1 DE 60121913 D1 DE60121913 D1 DE 60121913D1 DE 60121913 T DE60121913 T DE 60121913T DE 60121913 T DE60121913 T DE 60121913T DE 60121913 D1 DE60121913 D1 DE 60121913D1
Authority
DE
Germany
Prior art keywords
alanin
glycin
glycine
against hepatitis
containing drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121913T
Other languages
German (de)
Other versions
DE60121913T2 (en
Inventor
Masayoshi Yamauchi
Ajinomoto Co Sonaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of DE60121913D1 publication Critical patent/DE60121913D1/en
Application granted granted Critical
Publication of DE60121913T2 publication Critical patent/DE60121913T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Hepatitis remedy comprises alanine and glycine. ACTIVITY : Antiinflammatory; Hepatotropic. In assays using HepG2 cells addition of glycine and alanine at 0.02 mM significantly reduced galactosamine induced cell death (p is less than 0.05) compared to control or addition of glycine (0.1 mM). MECHANISM OF ACTION : None Given.
DE60121913T 2000-01-18 2001-01-12 ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS Expired - Lifetime DE60121913T2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000008658 2000-01-18
JP2000008658 2000-01-18
JP2000060097 2000-03-06
JP2000060097 2000-03-06
PCT/JP2001/000109 WO2001052834A1 (en) 2000-01-18 2001-01-12 Remedies for hepatitis containing alanine and glycine

Publications (2)

Publication Number Publication Date
DE60121913D1 true DE60121913D1 (en) 2006-09-14
DE60121913T2 DE60121913T2 (en) 2007-03-01

Family

ID=26583682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121913T Expired - Lifetime DE60121913T2 (en) 2000-01-18 2001-01-12 ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS

Country Status (7)

Country Link
US (1) US7208523B2 (en)
EP (1) EP1249235B1 (en)
AT (1) ATE334667T1 (en)
AU (1) AU2001225499A1 (en)
DE (1) DE60121913T2 (en)
ES (1) ES2264437T3 (en)
WO (1) WO2001052834A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656933A1 (en) * 2004-11-11 2006-05-17 Ajinomoto Co., Inc. A medicinal composition comprising L-alanine for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and use therof
JPWO2006061992A1 (en) * 2004-12-10 2008-06-05 味の素株式会社 Liver disease prevention / treatment composition
WO2007142297A1 (en) * 2006-06-09 2007-12-13 Ajinomoto Co., Inc. Composition for prevention/treatment of hepatic disease
GB201019628D0 (en) * 2010-11-19 2010-12-29 Reckitt Benckiser Nv Dyed coated bleach materials

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51115909A (en) * 1975-04-01 1976-10-13 Otsuka Pharmaceut Factory Inc A process for preparing amino acid parenteral injection mixed with a r educing sugar
DE2636828A1 (en) * 1976-08-16 1978-02-23 Fresenius Chem Pharm Ind (L)-Aminoacid mixt. for treating liver insufficiency - contains isoleucine, leucine, lysine, methionine and cysteine or cystine and non-essential aminoacid(s)
JPS58126767A (en) * 1982-01-22 1983-07-28 Ajinomoto Co Inc Elemental diet for hepatopathic patient
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
SU1470739A1 (en) * 1984-07-16 1989-04-07 Всесоюзный кардиологический научный центр АМН СССР Hexapeptide displaying hepatoprotective traits
JP3127484B2 (en) * 1991-02-28 2001-01-22 味の素株式会社 Hepatitis treatment
CA2078712A1 (en) * 1991-09-23 1993-03-24 Bernhard Sixt Composition comprising amino acids for the prevention of hypoxic damage and a process for its preparation
JP3168669B2 (en) * 1992-02-26 2001-05-21 味の素株式会社 Liver regeneration promoter
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
US20020198262A1 (en) 2002-12-26
EP1249235A1 (en) 2002-10-16
US7208523B2 (en) 2007-04-24
WO2001052834A1 (en) 2001-07-26
AU2001225499A1 (en) 2001-07-31
EP1249235B1 (en) 2006-08-02
ATE334667T1 (en) 2006-08-15
EP1249235A4 (en) 2004-07-28
DE60121913T2 (en) 2007-03-01
ES2264437T3 (en) 2007-01-01

Similar Documents

Publication Publication Date Title
DK1043399T5 (en) Hepatitis C virus cell culture system
FR2809329B1 (en) PORTABLE OXYGEN CONCENTRATOR
MX9708678A (en) Soluble, active hepatitis c virus protease.
TR200003635T2 (en) The use of Peg-IFN-ALFA and ribavirin in chronic hepatitis C treatment.
BR0113666A (en) Peptidomimetic protease inhibitors
ATE290877T1 (en) STABILIZED INSULIN PREPARATIONS
IL204319A (en) Kit for incorporation of single oxygen atom into a digested peptide of a protein comprising a peptidase and enriched 18o water
FR2855758B1 (en) COMPOSITION COMPRISING NS3 / NS4 POLYPROTEIN AND HCV NS5B POLYPEPTIDE, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR USE IN THERAPEUTICS
BR7600655U (en) Set of container and portable bucket activated by the user's foot
DE60121913D1 (en) ALANIN- AND GLYCIN-CONTAINING DRUGS AGAINST HEPATITIS
PT1115420E (en) TREATMENT OF HEPATITIS B INFECTION WITH TIMOSIN ALPHA 1 AND LAMIVUDINE
AR030648A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED EXCIPIENT
ATE430167T1 (en) HUMAN RECOMBINANT ANTIBODY AGAINST HEPATITIS C (HCV) NON-STRUCTURAL NS3 PROTEIN, NUCLEIC ACID AND USES THEREOF
NO20021856D0 (en) Koplingsdal
NO20084950L (en) New use of therapeutically useful peptides
DE60038023D1 (en) NEW GBV SEQUENCE
DE69104012D1 (en) Recombinant hepatitis delta antigen, method for its purification and use.
Propst et al. The effect of interferon alpha and prednisolone on the serum concentrations of the aminoterminal domain of procoHagen type ili (PHIP) and type IV (7-8 collagen) in patients with chronic hepatitis A. Hayasaka, H. Kohen, N. Yoshikawa, S. Iida, M. Ohto (Japan) Is spontaneous bacterial peritonitis a complication of hospitalization?
KATAYAMA et al. A simple purification procedure for rat pancreatic elastase and radioimmunoassay of the enzyme
Lee Cylic AMP induced Inhibition of Cyclin A Expression and Growth Arrest in HepG2 Human Hepatoma Cell Line
Woo et al. Hepatic Drug Clearance of Animal in Disease States I-Hepato-biliary Transport of Bromphenol Blue in Acute $ CCl_4 $ Intoxicated Rabbits
Goldin et al. Hepatic sinusoidal endothelial cells in alcoholic liver disease—Phenotypic changes and basement membrane protein formation
Helige et al. Inhibition of K1735-M2 melanoma cell invasion in vitro by retinoic acid
King Does community involvement lead to long-term pollution solutions?
尹志远 A Wonderful Idea

Legal Events

Date Code Title Description
8364 No opposition during term of opposition